4148 — All Cosmos Bio-Tech Holding Income Statement
0.000.00%
Last trade - 00:00
- TWD2.97bn
- TWD2.60bn
- TWD2.83bn
- 82
- 50
- 39
- 62
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,768 | 1,643 | 2,197 | 3,702 | 2,827 |
Cost of Revenue | |||||
Gross Profit | 393 | 372 | 594 | 1,138 | 588 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,700 | 1,540 | 1,924 | 3,035 | 2,637 |
Operating Profit | 67.9 | 103 | 273 | 667 | 190 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 104 | 150 | 322 | 634 | 258 |
Provision for Income Taxes | |||||
Net Income After Taxes | 38.7 | 98.2 | 237 | 456 | 189 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 35.7 | 82.2 | 198 | 368 | 139 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 35.7 | 82.2 | 198 | 373 | 151 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.607 | 1.28 | 3.09 | 5.65 | 2.13 |
Dividends per Share |